English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219710
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

AuthorsMateos, Maria Victoria; Orlowski, R. Z.; Ocio, Enrique M. ; Rodríguez-Otero, Paula; Reece, Donna; Moreau, Philippe; Munshi, Nikhil; Avigan, David E.; Siegel, David S.; Ghori, Razi; Farooqui, Mohammed Z. H.; Marinello, Patricia; San Miguel, Jesús F.
Issue Date2019
PublisherWiley-VCH
CitationBritish Journal of Haematology 186(5): e117-e121 (2019)
Publisher version (URL)https://doi.org/10.1111/bjh.15946
URIhttp://hdl.handle.net/10261/219710
DOIhttp://dx.doi.org/10.1111/bjh.15946
ISSN0007-1048
E-ISSN1365-2141
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.